Role of MMP-2, MMP-9 and VEGF as serum biomarker in early prognosis of renal cell carcinoma

被引:4
|
作者
Ahmad, S. [1 ]
Singh, V. [2 ]
Sinha, R. J. [2 ]
Srivastava, A. [1 ]
Mandhani, A. [1 ]
机构
[1] Sanjay Gandhi Post Grad Inst Med Sci, Dept Urol & Renal Transplantat, Rabareli Rd, Lucknow 226014, Uttar Pradesh, India
[2] King George Med Univ, Lucknow, Uttar Pradesh, India
关键词
RCC; MMP-2; MMP-9; VEGF; Biomarker;
D O I
10.1016/j.afju.2018.09.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Renal cell carcinoma epitomizes a diversified group of tumors which contributes more than 15,000 deaths annually worldwide. In spite of tremendous efforts to identify prognostic factors apart from grade, histology and tumor size, they are not so obvious yet to fulfill the requirement. In this study, the prognostic role of serum matrix metalloproteinase, (MMP)-2, 9, and vascular endothelial growth factor (VEGF) levels in patients with pre and postoperative renal cell carcinoma are evaluated to use, as biomarker. Patients and methods: A total of 100 patients with;I diagnosis of renal cell carcinoma included in the study. Additionally, hundred healthy kidney donors enrolled as control, serum MMP-2, MMP-9, and VEGF levels were analyzed in the serum of post and preoperative patients and parallel in control serum samples by ELBA method. Result: Most of the patients with RCC were found to have high concentrations of serum MMP-2, MMP-9, and VEGF. The levels of MMP-2 in the serum of preoperative patients ranged from 627 to 1117 ng/ml (833.90 +/- 111.91), postoperative MMP-2 range 302-913 (553.02 +/- 150.08), control range 122-384 (228.33 +/- 72.52). In MMP-9 pre-operative range 61.9-1233 (862.32 +/- 119.77), post-operative range 124-909 (552.88 +/- 151.91) and control range 42-467 (245.44 +/- 116.52 and in VEGF preoperative range was 0.792-2.214 (1.3.5 +/- 0.36), postoperative range was 0.315-1.917 (0.81 +/- 0.46) and in control it was 0.01-0.39 (0.10 +/- 0.09). We observed that preoperative levels of all three markers, were significantly increased if compared with postoperative and control levels (P = 0.001) however, no any significant correlation found when the levels correlated with grade., stage, size, and type for MMP-2 and MMP-9, but VEGF shows some significance, in comparison. Conclusion: The present data shows relevance and strong significant decrease in the level of MMP-2, MMP-9, and VEGF after surgery, so they could use as biomarkers in early disease diagnosis and also in monitoring disease recurrence.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 50 条
  • [1] The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma
    Aparna, Manikkath
    Rao, Lakshmi
    Kunhikatta, Vijayanarayana
    Radhakrishnan, Raghu
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2015, 44 (05) : 345 - 352
  • [2] The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma
    Song, Zhe
    Wang, Junfu
    Su, Qinghong
    Luan, Meng
    Chen, Xuemei
    Xu, Xiaoqun
    [J]. BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2021, 87 (05) : 521 - 528
  • [3] Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma
    Li, Yin
    Ma, Jun
    Guo, Qi
    Duan, Fangling
    Tang, Fu'ai
    Zheng, Pengyuan
    Zhao, Zhiguo
    Lu, Gaofeng
    [J]. DISEASES OF THE ESOPHAGUS, 2009, 22 (08): : 664 - 667
  • [4] Elevated serum levels of VEGF, bFGF, MMP-2, and MMP-9 in patients with Moyamoya disease
    Lim, M
    Wang, Y
    Bower, R
    Cheshier, S
    Sims, L
    Choi, S
    Harsh, G
    Steinberg, G
    Guccione, S
    [J]. STROKE, 2006, 37 (02) : 701 - 701
  • [5] Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma
    Patel, BP
    Shah, PM
    Rawal, UM
    Desai, AA
    Shah, SV
    Rawal, RM
    Patel, PS
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2005, 90 (02) : 81 - 88
  • [6] Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma
    Anna Goździalska
    Anna Wojas-Pelc
    Jagoda Drąg
    Paweł Brzewski
    Jerzy Jaśkiewicz
    Maciej Pastuszczak
    [J]. Molecular Biology Reports, 2016, 43 : 1027 - 1033
  • [7] MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer
    Quaranta, M.
    Daniele, A.
    Coviello, M.
    Venneri, M. T.
    Abbate, I.
    Caringella, M. E.
    Di Tardo, S.
    Divella, R.
    Trerotoli, P.
    Di Gennaro, M.
    Schittulli, F.
    Fransvea, E.
    Giannelli, G.
    [J]. ANTICANCER RESEARCH, 2007, 27 (5B) : 3593 - 3600
  • [8] Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma
    Gozdzialska, Anna
    Wojas-Pelc, Anna
    Drag, Jagoda
    Brzewski, Pawel
    Jaskiewicz, Jerzy
    Pastuszczak, Maciej
    [J]. MOLECULAR BIOLOGY REPORTS, 2016, 43 (10) : 1027 - 1033
  • [9] Heart failure and role of circulating MMP-2 and MMP-9
    Radosinska, Jana
    Barancik, Miroslav
    Vrbjar, Norbert
    [J]. PANMINERVA MEDICA, 2017, 59 (03) : 241 - 253
  • [10] The Role Of Mmp-9 And Mmp-2 In Coronary Arterial Remodeling
    Toutouzas, Konstantinos
    Tsiamis, Eleftherios
    Synetos, Andreas
    Markou, Virginia
    Drakopoulon, Maria
    Karabelas, John
    Tsioufis, Costas
    Stefanadi, Elli
    Tousoulis, Dimitris
    Stefanadis, Christodoulos
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (8A): : 242I - 243I